Matinas biopharma provides business update and 2022 strategic outlook

– end of phase 2 meeting with fda provides pathway to nda submission for mat2203 following confirmatory data to be generated in an additional cohort; cohort 5 in ongoing enact trial –
MTNB Ratings Summary
MTNB Quant Ranking